Is Stopping of Testosterone-Lowering Medication in Men Convicted of Sexual Offenses Associated With an Increase in Recidivism Risk?
Sexual Abuse · 2025
DOI: 10.1177/10790632241309628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sexual Abuse, 2025. Verfasst von Jochen Wolba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vitos Forensic-Psychiatric Outpatient Department (FPA) Hesse, Haina (Kloster)/Wiesbaden, Germany. Hauptthemen laut MEDLINE: Recidivism, Testosterone, Sex Offenses, Criminals. Die Arbeit nennt 83 Literaturangaben. Gefördert von: Vitos Forensic-Psychiatric Outpatient Department (FPA) in Hesse, Germany.
Abstract (Originalsprache)
There is some evidence that testosterone-lowering medications (TLM) may be an effective treatment for men convicted of sexual offenses by attenuating paraphilic sexual fantasies and behaviors and reducing the recidivism risk. To date, however, only little is known about the effects of TLM stopping on risk-relevant aspects. Therefore, the current study aimed at examining the recidivism risk as measured by Stable-2007 as well as official records of reoffenses in 29 men having stopped TLM treatment as compared to 37 men with ongoing TLM treatment. The Stable-2007 was rated retrospectively at 4 time points: committal to forensic treatment (T1), starting (T2) and stopping of TLM treatment (T3), and at reporting date (T4). There was a significant decrease in Stable-2007 scores over time, but there were no significant group differences. Within the stopped-TLM group, there were no significant differences between T3 and T4, implying that the recidivism risk remained stable over an average observation period of 4.5 years after TLM stopping. In addition, there was no significant difference in actual reoffending rates between the groups. For sexual reoffending, the percentages were 17.2% for the stopped-TLM group and 10.8% for the ongoing-TLM group. However, although the current results suggest that there is at least no increase in risk assessment (i.e., Stable-2007) after having stopped TLM, the actual reoffending rates of both groups were higher than expected. This once again demonstrates that TLM stopping decisions remain very difficult to make. Further studies are urgently needed to draw clearer conclusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vitos Forensic-Psychiatric Outpatient Department (FPA) Hesse, Haina (Kloster)/Wiesbaden, Germany.
- Institute for Forensic Psychology and Psychiatry, Saarland University Medical Center, University of the Saarland, Homburg (Saar), Germany.
- Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany.
- Institute for Sex Research and Forensic Psychiatry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID-Profile: Jochen Wolba, Daniel Turner, Peer Briken, Wolfgang Retz, Safiye Tozdan
Förderung
- Vitos Forensic-Psychiatric Outpatient Department (FPA) in Hesse, Germany
Zitieren
APA
Wolba, J., Turner, D., Briken, P., Freese, R., Retz, W., & Tozdan, S. (2025). Is Stopping of Testosterone-Lowering Medication in Men Convicted of Sexual Offenses Associated With an Increase in Recidivism Risk?. Sexual Abuse. https://doi.org/10.1177/10790632241309628
Vancouver
Wolba J, Turner D, Briken P, Freese R, Retz W, Tozdan S. Is Stopping of Testosterone-Lowering Medication in Men Convicted of Sexual Offenses Associated With an Increase in Recidivism Risk?. Sexual Abuse. 2025. doi:10.1177/10790632241309628
BibTeX
@article{Wolba2025,
author = {Wolba, Jochen and Turner, Daniel and Briken, Peer and Freese, Roland and Retz, Wolfgang and Tozdan, Safiye},
title = {Is Stopping of Testosterone-Lowering Medication in Men Convicted of Sexual Offenses Associated With an Increase in Recidivism Risk?},
journal = {Sexual Abuse},
year = {2025},
doi = {10.1177/10790632241309628}
}
EUVIMED